Clinical trials: Medical Adherence
Bacterial Infections, Acute Bacterial Skin and Skin Structure Infection
Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
The purpose of this study is to assess the effect of a new critical pathway (use of guideline-based patient identification criteria and for those who meet these criteria, use of dalbavancin) compared to usual care for the…
- Trial name
- NCT03233438
- Testing
- Dalbavancin, Usual Care
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Allergan
Hepatitis C, Chronic Hepatitis C
Impact of Patient Support by the Medical Staff on Adherence to Therapy With PegIntron Plus Rebetol (Study P04413)
The objective of this study is to assess the impact of participant care and support on treatment adherence. PegIntron pen and Rebetol will be administered to participants with Hepatitis C Virus (HCV) in accordance with approved…
- Trial name
- @dhere (NCT00704964)
- Testing
- PegIntron, Rebetol
- Volunteers
- 746 people
- Sponsor
- Merck Sharp & Dohme LLC
Hyponatremia, Syndrome of Inappropriate ADH (SIADH) Secretion
An Observational Study to Describe the Adherence to the SEOM Algorithm for the Treatment of Hyponatraemia in Spain
In 2014, the Spanish Sociedad Española de Oncología Médica (SEOM) algorithm for the treatment of hyponatraemia secondary to to syndrome of inappropriate antidiuretic hormone (SIADH) in oncology patients was developed.
- Trial name
- ALGA (NCT02548845)
- Where
- 4 sites in Spain
- Volunteers
- 70 people
- Sponsor
- Otsuka Pharmaceutical Europe Ltd
Renal Cell Carcinoma (RCC)
Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC
The study aims to assess treatment patterns and outcomes in advanced RCC patients in real world clinical practices across various real world databases. Four databases will be evaluated
- Trial name
- NCT04375150
- Testing
- Tyrosine kinase inhibitor (TKI), Immuno-oncology (IO)
- Where
- United States
- Volunteers
- 355 people
- Sponsor
- Pfizer
Acute Bacterial Skin and Skin Structure Infections
Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
This study will evaluate a new critical pathway (use of guideline-based patient identification criteria and for those who meet these criteria, use of dalbavancin) for the treatment of ABSSSI compared to usual care.
- Trial name
- NCT02961764
- Testing
- Usual Care, Dalbavancin
- Where
- 11 sites in United States
- Volunteers
- 313 people
- Sponsor
- Allergan
Pulmonary Disease, Chronic Obstructive
ADESPI: Adherence to Spiriva® in Patients With COPD (Chronic Obstructive Pulmonary Disease), Measured by Morisky-8 (MMAS-8) Scale, in Routine Medical Practice
The objective of this observational study is to collect and evaluate data on medication adherence of patients on maintenance COPD therapy with long-acting anticholinergic (e.g.
- Trial name
- NCT01388166
- Testing
- Education
- Where
- 90 sites in Hungary, Slovakia and 1 more
- Volunteers
- 1,253 people
- Sponsor
- Boehringer Ingelheim
Adolescent Idiopathic Scoliosis
Green Sun Medical Dynamic Scoliosis Brace
This is a pilot study to collect preliminary short-term data concerning the safety and performance of the Green Sun Dynamic brace in a sample of subjects with adolescent idiopathic scoliosis who are currently being treated with a…
- Trial name
- GSM (NCT03641469)
- Testing
- Green Sun Dynamic Brace
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- Green Sun medical
Schizophrenia, Mental Disorder
Open-label Study to Assess Usability of the Medical Information Device #1 (MIND1) System in Adults With Schizophrenia On Oral Aripiprazole
The purpose of this study is to determine the usability of the Medical Information Device #1 (MIND1) system in adults with schizophrenia who are treated with oral aripiprazole.
- Conditions
- Schizophrenia, Mental Disorder, Nervous System Diseases
- Trial name
- NCT02219009
- Testing
- MIND1 System
- Where
- 6 sites in United States
- Volunteers
- 67 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.